Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Invested Capital (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Return on Invested Capital data on record, last reported at 0.68% in Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 33.0% year-over-year to 0.68%; the TTM value through Dec 2025 reached 0.68%, down 33.0%, while the annual FY2025 figure was 0.92%, 71.0% down from the prior year.
  • Return on Invested Capital reached 0.68% in Q4 2025 per AMLX's latest filing, down from 0.37% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.37% in Q3 2025 and bottomed at 1.2% in Q3 2024.
  • Average Return on Invested Capital over 4 years is 0.29%, with a median of 0.23% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: crashed -120bps in 2024, then surged 157bps in 2025.
  • A 4-year view of Return on Invested Capital shows it stood at 0.83% in 2022, then skyrocketed by 110bps to 0.08% in 2023, then tumbled by -528bps to 0.35% in 2024, then crashed by -93bps to 0.68% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.68% in Q4 2025, 0.37% in Q3 2025, and 0.29% in Q2 2025.